Thus, we performed a molecular docking analysis of the bioactive compounds, and identified the one among them, i.e., 3α, 5α-cyclo-ergosta-7,9(11),22t-triene-6β-ol, which showed the highest binding affinity (−9.5 Kcal/mol) against the overexpressed anti-apoptotic protein receptor Bcl-2 of breast cancer. This evidence concerns the gene BCL2 and breast carcinoma.